Project: The role of ex vivo diagnostics in assigning drug causality in Severe Cutaneous Adverse Reactions
Trubiano Group
In this project you will utilise biological samples collected from a national registry of SCAR to help improve the sensitivity of ex vivo T-cell diagnostics, including flow cytometry and enzyme linked immunospot assay. You will compare and contrast a range of cellular inputs (e.g. blood, skin) and outputs (e.g. flow, ELISpot) to improve the sensitivity and specificity of these T-cell diagnostics and move them towards a beside diagnostic.
Project Site: Austin Health
Contact project supervisor for further
information and application enquiries
Trubiano Group
1 vacancies
We are a lab based at Austin Health within the Department of Infectious Diseases (Austin Health) with an interest in drug allergy/hypersensitivity research from translational to health services programs. In particular our "dry lab" focuses on low-risk penicillin and antibiotic allergy clinical trials and our "wet lab" on the development of translational ex vivo and in vitro T-cell diagnostics to assertain drug causality in Severe Cutaneous Adverse Reactions. Our lab collaborates with groups internationally, including North America, Europe and South Africa.
Trubiano Group Current Projects
-
The role of ex vivo diagnostics in assigning drug causality in Severe Cutaneous Adverse Reactions
PhD/MPhil, Master of Biomedical Science, Honours
Research degrees at the Doherty Institute are administered by the University of Melbourne.